Benitec Biopharma (NASDAQ:BNTC) Price Target Raised to $22.00

Benitec Biopharma (NASDAQ:BNTC) had its target price increased by Citizens Jmp from $20.00 to $22.00 in a research note released on Tuesday morning,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

BNTC has been the topic of a number of other reports. TD Cowen assumed coverage on Benitec Biopharma in a report on Monday, July 7th. They set a “buy” rating on the stock. Wall Street Zen upgraded Benitec Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Wednesday, October 8th. Citigroup reiterated an “outperform” rating on shares of Benitec Biopharma in a research note on Tuesday. Finally, Oppenheimer restated an “outperform” rating and issued a $29.00 target price (down previously from $35.00) on shares of Benitec Biopharma in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.83.

Benitec Biopharma Trading Down 24.0%

Shares of Benitec Biopharma stock opened at $12.00 on Tuesday. Benitec Biopharma has a 52-week low of $9.10 and a 52-week high of $17.15. The firm has a market capitalization of $315 million, a PE ratio of -8.16 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 54.67 and a quick ratio of 54.67. The company’s fifty day moving average price is $14.52 and its two-hundred day moving average price is $13.78.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings data on Thursday, September 25th. The biotechnology company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.18). On average, analysts expect that Benitec Biopharma will post -1.48 EPS for the current year.

Hedge Funds Weigh In On Benitec Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MYDA Advisors LLC grew its holdings in shares of Benitec Biopharma by 4.0% during the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock worth $677,000 after purchasing an additional 2,000 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in Benitec Biopharma during the 2nd quarter worth about $38,000. Bank of America Corp DE grew its holdings in Benitec Biopharma by 2,255.8% during the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,587 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Benitec Biopharma in the 2nd quarter valued at about $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Benitec Biopharma in the second quarter worth about $93,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.